Login to Your Account

Other News To Note

Wednesday, April 18, 2012
• Intellect Neurosciences Inc., of New York, entered a collaboration with the University California, Irvine, to test preclinical Alzheimer's disease vaccine candidate RV03. RV03 is a dual-acting peptide vaccine candidate designed to induce an immune response against beta amyloid and delta tau.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription